All In MedTech

Device Trial Radar · NCT04395131

Clearum High Flux Hemodialyzer Used in Hemodialysis for Subjects With End-Stage Renal Disease

Clearum High Flux Hemodialyzer: Safety and Performance Clinical Study

Last checked: Nov 19, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Apr 3, 2020

Primary completion

Aug 14, 2020

Study completion Aug 14, 2020

Sponsor

Lead sponsor
Mozarc Medical US LLCNot on our public-company list
Sponsor type
Industry
First posted
May 20, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will be a prospective, interventional, non-randomized, single-center study in 20 ESRD patients on hemodialysis. The study will compare performance of the Clearum HS dialyzer to typical values obtained with other commercially available high flux dialyzers. In addition, the Clearum HS dialyzer will be compared to a Fresenius FX80 dialyzer for a baseline (control) comparison. This will be a post-market study. The duration of the trial is 2 weeks for the FX80 control dialyzer + 6 weeks with the Clearum HS dialyzer used for 3x weekly high flux hemodialysis.

Conditions

  • End-stage Renal Disease

Interventions

  • Clearum HF HemodialyzerDevice

    the hemodialyzer will be used 3x week for 3.5-4.5 hours with a Qb of at least 350 ml/min

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate performance of small-solute (toxin) removalTime frame: End of dialysis treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • DaVita Clinical Research Germany

    Düsseldorf, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.